Cargando…

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reade, Chad A, Ganti, Apar Kishor
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726075/ https://www.ncbi.nlm.nih.gov/pubmed/19707410

Ejemplares similares

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Current concepts in the management of small cell lung cancer
por: Ganti, Apar Kishor, et al.
Publicado: (2013)

Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database
por: Anggondowati, Trisari, et al.
Publicado: (2020)

Promising trends in lung cancer care, but are we overlooking the majority?
por: Sharma, Bhavina, et al.
Publicado: (2023)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using (47)Sc-conjugated cetuximab
por: Kim, Da-Mi, et al.
Publicado: (2023)

Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer
por: Keit, Emily, et al.
Publicado: (2021)

Cetuximab Combined With Sonodynamic Therapy Achieves Dual-Modal Image Monitoring for the Treatment of EGFR-Sensitive Non-Small-Cell Lung Cancer
por: Qiu, Guanhua, et al.
Publicado: (2022)

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
por: Delaney, Christopher, et al.
Publicado: (2015)

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
por: Macha, Muzafar A, et al.
Publicado: (2013)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
por: Arnold, Abram, et al.
Publicado: (2023)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Cetuximab and biomarkers in non-small-cell lung carcinoma
por: Patil, Nitin, et al.
Publicado: (2012)

Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small cell lung cancer: a pooled analysis based on individual patient data of CALGB/Alliance trials
por: Yang, Lexie Zidanyue, et al.
Publicado: (2022)

RNA-based therapies: A cog in the wheel of lung cancer defense
por: Khan, Parvez, et al.
Publicado: (2021)

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
por: Rothschild, Sacha I.
Publicado: (2015)

HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC)
por: Potti, Anil, et al.
Publicado: (2005)

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
por: Zhang, Keqiang, et al.
Publicado: (2020)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)

Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer
por: Crintea, Andreea, et al.
Publicado: (2023)

Rational use of cetuximab in the treatment of advanced non-small cell lung cancer
por: Aggarwal, Charu, et al.
Publicado: (2009)

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
por: Lee, Sang-Kyu, et al.
Publicado: (2018)

Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab
por: Santis, Rita De, et al.
Publicado: (2014)

Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer
por: Shao, Changjian, et al.
Publicado: (2021)

Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles
por: Qian, Yichun, et al.
Publicado: (2014)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance
por: Wang, Yuetong, et al.
Publicado: (2016)

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
por: Chhouri, Houssein, et al.
Publicado: (2023)

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
por: ZHOU, BO, et al.
Publicado: (2016)

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
por: Nishii, Kazuya, et al.
Publicado: (2021)

Pancytopenia due to iron deficiency worsened by iron infusion: a case report
por: Ganti, Apar Kishor, et al.
Publicado: (2007)

The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab
por: Froelich, Matthias F., et al.
Publicado: (2018)

Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer
por: Bhatt, Vijaya Raj, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_crodjgs06l687ervtlfb2adqpq